Tenax Therapeutics Inc. Common Stock (NASDAQ: TENX)
58 Days left to seek lead plaintiff status.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) TNX-103 was less effective than Defendants had led investors to believe; (ii) accordingly, TNX-103’s overall clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.